Skip to content

The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01070589
Enrollment
24
Registered
2010-02-18
Start date
2010-02-28
Completion date
2012-07-31
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Growth hormone secretion, Anaerobic exercise

Brief summary

The aim of the present study is to asses the effect of obesity on anaerobic exercise's growth hormone (GH) response.

Detailed description

Exercise is a potent physiological stimulator of growth hormone (GH) release. GH is an important factor in the distribution of fat and lean tissue in the body. Previous studies suggested that the GH response to aerobic exercise may be attenuated by obesity. The effect of obesity on GH response to anaerobic effort is unclear. The aim of the present study is to asses the effect of obesity on anaerobic exercise's GH response. We will recruit 12 obese (BMI \> 30) healthy adults and 12 age and gender matched normal weight (BMI \< 25) controls. All the participants will conduct a wingate anaerobic test (30 seconds of intense effort against resistance calculated by the individual's body weight). Blood sample for GH level will be collected at 5 different time (0, 20, 30, 40 and 60 minutes after the test). We will compare the GH response in the two groups.

Interventions

None listed

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy female * Age 18-40

Exclusion criteria

* Male * Age \<18, \>40 * Heart, Liver, Kidney or Hypophyseal disease * Medications that may alter GH secretion (eg Steroids, Eltroxin)

Countries

Israel

Contacts

Primary ContactNoa rakover klein, MD
noa.rakover@gmail.com972-77-4920014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026